Oncotarget

Meta-Analysis:

PPARG c.1347C>T polymorphism is associated with cancer susceptibility: from a case-control study to a meta-analysis

Hao Ding, Yuanmei Chen, Hao Qiu, Chao Liu, Yafeng Wang, Mingqiang Kang and Weifeng Tang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:102277-102290. https://doi.org/10.18632/oncotarget.20925

Metrics: PDF 587 views  |   HTML 1354 views  |   ?  


Abstract

Hao Ding1,*, Yuanmei Chen2,*, Hao Qiu3,*, Chao Liu4, Yafeng Wang5, Mingqiang Kang6 and Weifeng Tang6

1Department of Respiratory Disease, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, China

2Department of Thoracic Surgery, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian Province, China

3Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu Province, China

4Department of Cardiothoracic Surgery, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, China

5Department of Cardiology, The People's Hospital of Xishuangbanna Dai Autonomous Prefecture, Jinghong, Yunnan Province, China

6Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China

*These authors contributed equally to this work

Correspondence to:

Weifeng Tang, email: twf001001@126.com

Mingqiang Kang, email: Mingqiang_Kang @126.com

Keywords: PPARG, polymorphism, non-small cell lung cancer, risk

Received: July 03, 2017     Accepted: August 27, 2017     Published: September 15, 2017

ABSTRACT

Recently, several studies suggested that PPARG c.1347C>T polymorphism was correlated with cancer risk. However, past results remained controversial. In this study, we performed a case-control study on the relationship of PPARG c.1347C>T polymorphism with risk of non-small cell lung cancer (NSCLC) and subsequently carried out a meta-analysis to further assess the association between PPARG c.1347C>T and overall cancer. In our case-control study, after adjusting by age, sex, body mass index (BMI), smoking and drinking, a tendency to increased NSCLC risk was noted (CT/TT vs. CC: adjusted OR, 1.21; 95% CI, 0.97–1.51; P = 0.097). In the meta-analysis, we found a significant association between PPARG c.1347C>T polymorphism and overall cancer risk (T vs. C: OR, 1.13; 95% CI, 1.03–1.23; P = 0.006; TT vs. CC: OR, 1.29; 95% CI, 1.07–1.56; P = 0.008, CT/TT vs. CC: OR, 1.11; 95% CI, 1.02–1.21; P = 0.014 and TT vs. CT/CC: OR, 1.26; 95% CI, 1.04–1.52; P = 0.016). In a subgroup analysis by ethnicity, evidence of significant association between PPARG c.1347C>T polymorphism and cancer risk was found among Asians and mixed populations. In a subgroup analysis by cancer type, PPARG c.1347C>T polymorphism was associated with risk of esophageal cancer and glioblastoma. In addition, in a subgroup analysis by origin of cancer cell, evidence of significant association between PPARG c.1347C>T polymorphism and cancer risk was also found among epithelial tumor. In conclusion, the findings indicate PPARG c.1347C>T polymorphism may increase the susceptibility of cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20925